C4 Therapeutics, Inc.

C4 Therapeutics trades at a microscopic $0.4B market cap yet carries an astronomical 72.9 RSI, suggesting severe overbought conditions despite no profitable earnings (P/E n/a). The 19.35% short float indicates meaningful skepticism from bears, creating potential squeeze dynamics if momentum sustains, though the extreme RSI reading typically precedes pullbacks in small-cap biotech. The valuation compression and technical extremes imply the stock has already priced in substantial optimism—either a clinical catalyst justifies current levels or mean reversion risk looms significant.